Prevention of relapse and recurrence in adults with major depressive disorder: Systematic review and meta-analyses of controlled trials

International Journal of Neuropsychopharmacology

Volumn 19, Issue 2, 2016, Pages

  Sim, Kang ^a,b   Lau, Wai Keat ^a   Sim, Jordan ^a   Sum, Min Yi ^b   Baldessarini, Ross J ^c,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSTITUTE OF MENTAL HEALTH   (Singapore)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MCLEAN HOSPITAL   (United States)

Author keywords

Antidepressants; Depression; Major depression; Psychotherapy; Recurrence; Relapse

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DESVENLAFAXINE; DOSULEPIN; DULOXETINE; FLUOXETINE; FLUVOXAMINE; GEPIRONE; IMIPRAMINE; LITHIUM; MAPROTILINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; NOMIFENSINE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; QUETIAPINE; REBOXETINE; SELEGILINE; SERTRALINE; VENLAFAXINE; ZIMELDINE;

COGNITIVE BEHAVIORAL THERAPY; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; META ANALYSIS; MINDFULNESS; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RECURRENT DISEASE; RELAPSE; REVIEW; SYSTEMATIC REVIEW; CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSIVE DISORDER, MAJOR; MULTIMODALITY CANCER THERAPY; PROCEDURES; SECONDARY PREVENTION;

ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; CONTROLLED CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; HUMANS; PSYCHOTHERAPY; RECURRENCE; SECONDARY PREVENTION;

EID: 84979220817     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyv076     Document Type: Review

References (120)

1. Alexopoulos GS, Meyers BS, Young RC, Kalayam B, Kakuma T, Gabrielle M, Sirey JA, Hull J (2000) Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry 57:285-290.
2. Amsterdam JD, Bodkin JA (2006) Selegiline transdermal system in the prevention of relapse of major depressive disorder: 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol 26:579-586.
3. Baldessarini RJ (2013) Chemotherapy in Psychiatry, 3rd edition. New York: Springer Press.
4. Baldessarini RJ, Tondo L, Ghiani C, Lepri B (2010) Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psych 167:934-941.
5. Baldessarini RJ, Lau WK, Sim J, Sum MY, Sim K (2015) Duration of initial antidepressant treatment and subsequent relapse of major depression. J Clin Psychopharmacol 35:75-76.
6. Bauer M, Bschor T, Kunz D, Berghofer A, Strohle A, Miller-Oerlinghausen B (2000) Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psych 157:1429-1435.
7. Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ (2015) World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Unipolar Depressive Disorders. Guidelines for biological treatment of unipolar depressive disorders. World J Biol Psychiatry 16:76-95.
8. Bialos D, Giller E, Jatlow P, Docherty J, Harkness L (1982) Recurrence of depression after discontinuation of long-term amitriptyline treatment. Am J Psych 139:325-329.
9. Bjork K (1983) The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders: double-blind placebo-controlled study. Acta Psychiatr Scand 308:182-189.
10. Bockting CL, Schene AH, Spinhoven P, Koeter MW, Wouters LF, Huyser J, Kamphuis JH (2005) Preventing relapse/recurrence in recurrent depression with cognitive therapy: randomized controlled trial. J Consult Clin Psychol 73:647-657.
11. Bockting CL, Spinhoven P, Wouters LF, Koeter MW, Schene AH (2009) Long-term effects of preventive cognitive therapy in recurrent depression: 5.5-year follow-up study. J Clin Psychiatry 70:1621-1628.
12. Bondolfi G, Jermann F, der Linden MV, Gex-Fabry M, Bizzini L, Rouget BW, Myers-Arrazola L, Gonzalez C, Segal Z, Aubry JM, Bertschy G (2010) Depression relapse prophylaxis with Mindfulness-Based Cognitive Therapy: replication and extension in the Swiss health care system. J Affect Disord 122:224-231.
13. Borges S, Chen Y-F, Laughren TP, Temple R, Patel HD, David PA, Mathis M, Unger E, Yang P, Khin NA (2014) Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration. J Clin Psychiatry 75:205-214.
14. Boulenger JP, Loft H, Florea I (2012) Randomized clinical study of Lu-AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 26:1408-1416.
15. Bschor T, Berghöfer A, Ströhle A, Kunz D, Adli M, Müller-Oerlinghausen B, Bauer M (2002) How long should the lithium augmentation strategy be maintained? One-year follow-up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol 22:427-430.
16. Cook BL, Helms PM, Smith RE, Tsai M (1986) Unipolar depression in the elderly: reoccurrence on discontinuation of tricyclic antidepressants. J Affect Disord 10:91-94.
17. Coppen A, Ghose K, Montgomery S, Rama RV, Bailey J, Jorgensen A (1978) Continuation therapy with amitriptyline in depression. Br J Psychiatry 133:28-33.
18. Cox GR, Fisher CA, De Silva S, Phelan M, Akinwale OP, Simmons MB, Hetrick SE (2012) Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents. Cochrane Database Syst Rev 11:CD007504.
19. Cunningham LA (1997) Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry 9:157-164.
20. Davidson J, Raft D (1984) Use of phenelzine in continuation therapy. Neuropsychobiology 11:191-194.
21. Dobson KS, Hollon SD, Dimidjian S, Schmaling KB. Kohlenberg RJ, Gallop RJ, Rizvi SL, Gollan JK, Dunner DL, Jacobson NS (2008) Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. J Consult Clin Psychol 76:468-477.
22. Doogan DP, Caillard V (1992) Sertraline in the prevention of depression. Br J Psychiatry 160:217-222.
23. Entsuah AR, Rudolph RL, Hackett D, Miska S (1996) Efficacy of venlafaxine and placebo during long-term treatment of depression: pooled analysis of relapse rates. Int Clin Psychopharmacol 11:137-145.
24. Fava GA, Rafanelli C, Grandi S, Conti S, Belluardo P (1998) Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. Arch Gen Psychiatry 55:816-820.
25. Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL (1998) Double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 10:145-150.
26. Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Murck H, Rosenbaum JF (2005) Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 25:441-447.
27. Feiger AD, Bielski RJ, Bremner J, Heiser JF, Trivedi M, Wilcox CS, Roberts DL, Kensler TT, McQuade RD, Kaplita SB, Archibald DG (1999) Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol 14:19-28.
28. Ferreri M, Colonna L, Leger JM (1997) Efficacy of amineptine in the prevention of relapse in unipolar depression. Int Clin Psychopharmacol 12:S39-45.
29. Forte A, Baldessarini RJ, Tondo L, Vázquez G, Pompili M, Girardi P (2015) Long-term morbidity in bipolar-I, bipolar-II, and major depressive disorders. J Affect Disord 178:71-78.
30. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ (1990) Three-year outcomes of maintenance therapies in recurrent depression. Arch Gen Psychiatry 47:1093-1099.
31. Gagne GG Jr, Furman MJ, Carpenter LL, Price LH (2000) Efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients. Am J Psych 157:1960-1965.
32. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653-661.
33. Gelenberg AJ et al (2003) Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry 54:806-817.
34. Georgotas A (1985) Affective disorders: pharmacotherapy. Compr Psychiatry 4:821-833.
35. Georgotas A, McCue RE, Cooper TB (1989) Placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 46:783-786.
36. Gilaberte I, Montejo AL, de la Gandara J, Perez-Sola V, Bernardo M, Massana J, Martin-Santos R, Santiso A, Noquera R, Casais L, Perez-Camo V, Arias M, Judge R (2001) Fluoxetine in the prevention of depressive recurrences: double-blind study. J Clin Psychopharmacol 21:417-424.
37. Glen AI, Johnson AL, Sheperd M (1984) Continuation therapy with lithium and amitriptyline in unipolar depressive illness: randomized, double-blind, controlled trial. Psychol Med 14:37-50.
38. Glue P, Donovan MR, Kolluri S, Emir B (2010) Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Aus New Zeal J Psychiatry 44:697-705.
39. Golden RN, Nemeroff CB, McSorley P, Pitts CD, Dubé EM (2002) Efficacy and tolerability of controlled-release and immediaterelease paroxetine in the treatment of depression. J Clin Psychiatry 63:577-584.
40. Goodwin GM, Emsley R, Rembry S, Rouillon F (2009) Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 70:1128-1137.
41. Gortner ET, Gollan JK, Dobson KS, Jacobson NS (1998) Cognitivebehavioral treatment for depression: relapse prevention. J Consult Clin Psychol 66:377-384.
42. Greenberg PE, Leong SA, Birnbaum HG, Robinson RL (2003) Economic burden of depression with painful symptoms. J Clin Psychiatry 64:17-23.
43. Gupta S, Tobiansky R, Bassett P, Warner J (2008) Efficacy of maintenance electroconvulsive therapy in recurrent depression: a naturalistic study. J ECT 24:191-194
44. Harrison W, Rabkin J, Stewart JW, McGrath PJ, Tricamo E, Quitkin F (1986) Phenelzine for chronic depression: a study of continuation treatment. J Clin Psychiatry 47:346-349.
45. Hochstrasser B, Isaksen PM, Koponen H, Lauritzen L, Mahnert FA, Rouillon F, Wade AG, Andersen M, Pedersen SF, Swart JC, Nil R (2001) Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry 178:304-310.
46. Hollon SD, DeRubeis RJ, Shelton RC, Amsterdam JD, Salomon RM, O'Reardon JP, Lovett ML, Young PR, Haman KL, Freeman BB, Gallop R (2005) Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 62:417-422.
47. Jarrett RB, Kraft D, Doyle J, Foster BM, Eaves GG, Silver PC (2001) Preventing recurrent depression using cognitive therapy with and without a continuation phase: randomized clinical trial. Arch Gen Psychiatry 58:381-388.
48. Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzi JR, Nayak DD, Howard A (1982) Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar I1 illness: prospective, placebo-controlled comparison. Arch Gen Psychiatry 39:1065-1069.
49. Kasper S, Volz HP, Moller HJ, Dienel A, Kieser M (2008) Continuation and long-term maintenance treatment with Hypericum extract WS-5570 after recovery from an acute episode of moderate depression: double-blind, randomized, placebo controlled long-term trial. Eur Neuropsychopharmacol 18:803-813.
50. Katon W, Rutter C, Ludman EJ, Von Korff M, Lin E, Simon G, Bush T, Walker E, Unützer J (2001) Randomized trial of relapse prevention of depression in primary care. Arch Gen Psychiatry 58:241-247.
51. Kelin K, Berk M, Spann M, Sagman D, Raskin J Walker D, Perahia D (2010) Duloxetine 60 mg/day for the prevention of depressive recurrences: post hoc analyses from a recurrence prevention study. Int J Clin Pract 64:719-726.
52. Keller MB, Kocsis JH, Thase ME, Gelenberg AJ, Rush AJ, Koran L, Schatzberg A, Russell J, Hirschfeld R, Klein D, McCullough JP, Fawcett JA, Kornstein S, LaVange L, Harrison W (1998) Maintenance phase efficacy of sertraline for chronic depression: randomized controlled trial. JAMA 280:1665-1672.
53. Keller MB, Ruwe FJ, Janssens CJ, Sitsen JM, Jokinen R, Janczewski J (2005) Relapse prevention with gepirone-ER in outpatients with major depression. J Clin Psychopharmacol 25:79-84.
54. Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT (2007a) Prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) study: outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 68:1246-1256.
55. Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Dunlop BW, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen R, Yan B, Ahmed S, Schmidt M (2007b) Prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry 62:1371-1379.
56. Kellner CH, Knapp RG, Petrides G, Rummans TA, Husain MM, Rasmussen K, Mueller M, Bernstein HJ, O'Connor K, Smith G, Biggs M, Bailine SH, Malur C, Yim E, McClintock S, Sampson S, Fink M (2006) Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry 63:1337-1344.
57. Kishimoto A, Mizukawa R, Matsuzaki F, Hazama H, Kamase H, Tanaka K, Kunimoto N (1994) Prophylactic effect of mianserin on recurrent depression. Acta Psychiatr Scand 89:46-51.
58. Klein DN, Santiago NJ, Vivian D, Blalock JA, Kocsis JH, Markowitz JC, McCullough Jr JP, Rush AJ, Trivedi MH, Arnow BA, Dunner DL, Manber R, Rothbaum B, Thase ME, Keitner GI, Miller IW, Keller MB (2004) Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression. J Consult Clin Psychol 72:681-688.
59. Klerman GL, DiMascio A, Weissman M, Prusoff B, Paykel ES (1974) Treatment of depression by drugs and psychotherapy. Am J Psych 131:186-191.
60. Klysner R, Bent-Hansen J, Hansen HL, Lunde M, Pleidrup E, Poulsen DL, Andersen M, Petersen HE (2002) Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebocontrolled study of maintenance therapy. Br J Psychiatry 181:29-35.
61. Kocsis JH, Friedman RA, Markowitz JC, Leon AC, Miller NL, Gniwesch L, Parides M (1996) Maintenance therapy for chronic depression. A controlled clinical trial of desipramine. Arch Gen Psychiatry 53:769-776.
62. Kocsis JH, Thase ME, Trivedi MH, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pederson RD, Yan B, Ahmed S, Musgnung J, Ninan PT, Keller MB (2007) Prevention of recurrent episodes of depression with venlafaxine-ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry 68:1014-1023.
63. Kok RM, Heeren TJ, Nolen WA (2011) Continuing treatment of depression in the elderly: a systematic review and metaanalysis of double-blinded randomized controlled trials with antidepressants. Am J Geriat Psychiatry 19:249-255.
64. Kornstein SG, Bose A, Li D, Saikali KG, Gandhi C (2006) Escitalopram maintenance treatment for prevention of recurrent depression: randomized, placebo-controlled trial. J Clin Psychiatry 67:1767-1775.
65. Kupfer DJ, Frank E, Perel JM, Cornes C, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ (1992) Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 49:769-773.
66. Kuyken W, Byford S, Taylor RS, Watkins E, Holden E, White K, Barrett B, Byng R, Evans A, Mullan E, Teasdale JD (2008) Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol 76:966-978.
67. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, Parikh SV, Patten SB, Ravindran AV (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 117(Supp 1):S26-43.
68. Lauritzen L, Odgaard K, Clemmesen L, Lunde M, Ohrstrom J, Black C, Bech P (1996) Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. Acta Psychiatr Scand 94:241-251.
69. Lendresse PH, Chen MC, LeMarie JC (1985) Traitement prolongé par nomifensine 75 mg dans les états dépressifs neurotiques et reactionnels. Psychiatrie Francaise 16:156-158.
70. Lepine JP, Caillard V, Bisserbe JC, Troy S, Hotton JM, Boyer P (2004) Randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psych 161:836-842.
71. Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H (2010) Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety 27:964-976.
72. Ma SH, Teasdale JD (2004) Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. J Consult Clin Psychol 72:31-40.
73. Maj M, Veltro F, Pirozzi R, Lobrace S, Magliano L (1992) Pattern of recurrence of illness after recovery from an episode of major depression: prospective study. Am J Psych 149:795-800.
74. Mathew KL, Whitford HS, Kenny MA, Denson LA (2010) Longterm effects of mindfulness-based cognitive therapy as a relapse prevention treatment for major depressive disorder. Behav Cogn Psychother 38:561-576.
75. Mindham RH, Howland C, Shepherd M (1973) Evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychol Med 3:5-17.
76. Montgomery SA, Dunbar G (1993a) Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 8:189-195.
77. Montgomery SA, Dufour H, Brion S, Gailledreau J, Laqueille X, Ferrey G, Moron P, Parant-Lucena N, Singer L, Danion JM, Beuzen JN, Pierredoin MA (1988) Prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 153:S69-76.
78. Montgomery SA, Rasmussen JG, Tanghøj P (1993b) A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 8:181-188.
79. Montgomery SA, Reimitz PE, Zivkov M (1998) Mirtazapine vs. amitriptyline in the long-term treatment of depression: double-blind placebo-controlled study. Int Clin Psychopharmacol 13:63-73.
80. Montgomery SA, Entsuah R, Hackett D, Kunz NR, Rudolph RL (2004) Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry 65:328-336.
81. Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D (1995) Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. The BMJ 310:441-445.
82. Old Age Depression Interest Group (OADIG) (1993) How long should the elderly take antidepressants? Double-blind placebo-controlled study of continuatiodprophylaxis therapy with dothiepin. Br J Psychiatry 162:175-182.
83. Perahia DG, Gilaberte I, Wang F, Wiltse CG, Huckins SA, Clemens JW, Montgomery SA, Montejo AL, Detke MJ (2006) Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry 188:346-353.
84. Pilling S, Anderson I, Goldberg D, Meader N, Taylor C (2009) Two guideline development groups: depression in adults, including those with a chronic physical health problem: summary of NICE guidance. The BMJ 339:b4108.
85. Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss CB, Johnson WE (1984) Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 41:1096-1104.
86. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Wager SG, Nunes E, Rabkin JG, Tricamo E, Markowitz J, Klein DF (1989) Phenelzine and imipramine in mood reactive depressives: further delineation of the syndrome of atypical depression. Arch Gen Psychiatry 46:787-793.
87. Reynolds CF III, Frank E, Perel JM, Imber SD, Cornes C, Miller MD, Mazumdar S, Houck PR, Dew MA, Stack JA, Pollock BG, Kupfer DJ (1999) Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: randomized controlled trial in patients older than 59 years. JAMA 28:39-45.
88. Reynolds CF III, Dew MA, Pollock BG, Mulsant BH, Frank E, Miller MD, Houck PR, Mazumdar S, Butters MA, Stack JA, Schlernitzauer MA, Whyte EM, Gildengers A, Karp J, Lenze E, Szanto K, Bensasi S, Kupder DJ (2006) Maintenance treatment of major depression in old age. N Engl J Med 354:1130-1138.
89. Rickels K, Montgomery SA, Tourian KA, Guelfi JD, Pitrosky B, Padmanabhan SK, Germain JM, Leurent C, Brisard C (2010) Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. J Clin Psychopharmacol 30:18-24.
90. Robert P, Montgomery SA (1995) Citalopram in doses of 20-60 mg is effective in depression relapse prevention: placebo-controlled 6 month study. Int Clin Psychopharmacol 10:S29-35.
91. Robinson DS, Lerfald SC, Bennett B, Laux D, Devereaux E, Kayser A, Corcella J, Albright D (1991) Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study. Psychopharmacol Bull 27:31-39.
92. Rosenthal JZ, Boyer P, Vialet C, Hwang E, Tourian KA (2013) Efficacy and safety of desvenlafaxine 50 mg/day for prevention of relapse in major depressive disorder:a randomized controlled trial. J Clin Psychiatry 74:158-166.
93. Rouillon F, Phillips R, Serrurier D, Ansart E, Gérard MJ (1989) Recurrence of unipolar depression and efficacy of maprotiline. Encephale 15:527-34.
94. Rouillon F, Warner B, Pezous N, Bisserbe JC (2000) Milnacipran efficacy in the prevention of recurrent depression: 12-month placebo-controlled study. Int Clin Psychopharmacol 15:133-140.
95. Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, Greenberg RM, Crowe RR, Cooper TB, Prudic J (2001) Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: randomized controlled trial. JAMA 285:1299-1307.
96. Schmidt ME, Fava M, Robinson JM, Judge R (2000) Efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry 61:851-857.
97. Segal ZV, Bieling P, Young T, MacQueen G, Cooke R, Martin L, Bloch R, Levitan RD (2010) Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Arch Gen Psychiatry 67:1256-1264.
98. Shea MT, Elkin I, Imber SD, Sotsky SM, Watkins JT, Collins JF, Pilkonis PA, Beckham E, Glass DR, Dolan RT, Parlodd MB (1992) Course of depressive symptoms over follow-up: findings from the National Institute of Mental Health treatment of depression collaborative research program. Arch Gen Psychiatry 49:782-787.
99. Sheets ES, Wilcoxon-Craighead L, Brosse AL, Hauser M, Madsen JW, Edward-Craighead W (2013) Prevention of recurrence of major depression among emerging adults by a group cognitive behavioral/interpersonal intervention. J Affect Disord 147:425-430.
100. Shimazu K, Shimodera S, Mino Y, Nishida A, Kamimura N, Sawada K, Fujita H, Furukawa TA, Inoue S (2011) Family psychoeducation for major depression: randomised controlled trial. Br J Psychiatry 198:385-390.
101. Shimodera S, Furukawa TA, Mino Y, Shimazu K, Nishida A, Inoue S (2012) Cost-effectiveness of family psychoeducation to prevent relapse in major depression: results from a randomized controlled trial. BMC Psychiatry 12:40-45.
102. Silverstone PH, Ravindran A (1999) Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 60:22-28.
103. Stein MK, Rickels K, Weise CC (1980) Maintenance therapy with amitriptyline: controlled trial. Am J Psych 137:370-371.
104. Stewart JW, Tricamo E, McGrath PJ, Quitkin FM (1997) Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission. Am J Psych 154:31-36.
105. Teasdale JD, Segal ZV, Williams JM, Ridgeway VA, Soulsby JM, Lau MA (2000) Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 68:615-623.
106. Terra JL, Montgomery SA (1998) Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol 13:55-62.
107. Thase ME, Nierenberg AA, Keller MB, Panagides J (2001) Efficacy of mirtazapine for prevention of depressive relapse: placebocontrolled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 62:782-788.
108. Thase ME, Gelenberg A, Kornstein SG, Kocsis JH, Trivedi MH, Ninan P, Li T, Pedersen R, Keller M (2011) Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study. J Psychiatr Res 45:412-420.
109. Thomas CM, Morris S (2003) Cost of depression among adults in England in 2000. Br J Psychiatry 183:514-519.
110. Undurraga J, Baldessarini RJ (2012) A 30-year meta-analytic review of antidepressant efficacy in acute major depression. Neuropsychopharmacology 37:851-864.
111. van Beusekom BS, van den Broek WW, Birkenhäger TK (2007) Long-term follow-up after successful electroconvulsive therapy for depression: 4- to 8-year naturalistic follow-up study. J ECT 23:17-20.
112. van den Broek WW, Birkenhager TK, Mulder PG, Bruijn JA, Moleman P (2006) Imipramine is effective in preventing relapse in electroconvulsive therapy-responsive depressed inpatients with prior pharmacotherapy treatment failure: randomized, placebo-controlled trial. J Clin Psychiatry 67:263-268.
113. Van Praag H, De Haan S (1980) Depression vulnerability and 5-hydroxytryptophan prophylaxis. Psychiatry Res 3:75-83.
114. Versiani M, Mehilane L, Gaszner P, Arnaud CR (1999) Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 60:400-406.
115. Weihs KL, Houser TL, Batey SR, Ascher JA, Bolden-Watson C, Donahue RM, Metz A (2002) Continuation phase treatment with bupropion-SR effectively decreases the risk for relapse of depression. Biol Psychiatry 51:753-761.
116. Wilkinson P, Izmeth Z (2012) Continuation and maintenance treatments for depression in older people. Cochrane Database Syst Rev 11:CD006727.
117. Williams N, Simpson AN, Simpson K, Nahas Z (2009) Relapse rates with long-term antidepressant drug therapy: a metaanalysis. Hum Psychopharmacol 24:401-408.
118. Wilson KCM, Mottram PG, Ashworth L, Abou-saleh MT (2003) Older community residents with depression: long-term treatment with sertraline. Br J Psychiatry 182:492-497.
119. World Health Organization (WHO) (2012) Global burden of disease: depression, 2012. http://www.who.int/mediacentre/factsheets/fs369/en/: Accessed 7 May 2015.
120. Yildiz A, Mantar A, Simsek S, Onur E, Gokmen N, Fidaner H (2010) Combination of pharmacotherapy with electroconvulsive therapy in prevention of depressive relapse: pilot controlled trial. J ECT 26:104-110.